[go: up one dir, main page]

MA27737A1 - Dérivés de l'acide 3-(2-phényloxazol-4-ylméthoxy)cyclohexylméthoxyacétique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose - Google Patents

Dérivés de l'acide 3-(2-phényloxazol-4-ylméthoxy)cyclohexylméthoxyacétique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose

Info

Publication number
MA27737A1
MA27737A1 MA28460A MA28460A MA27737A1 MA 27737 A1 MA27737 A1 MA 27737A1 MA 28460 A MA28460 A MA 28460A MA 28460 A MA28460 A MA 28460A MA 27737 A1 MA27737 A1 MA 27737A1
Authority
MA
Morocco
Prior art keywords
derivatives
treatment
cyclohexylmethoxyacetic
phenyloxazol
ylmethoxy
Prior art date
Application number
MA28460A
Other languages
English (en)
Inventor
Christian Stapper
Dirk Gretzke
Heiner Glombik
Eugen Falk
Jochen Goerlitzer
Stefanie Keil
Hans-Ludwig Schaefer
Wolfgang Wendler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA27737A1 publication Critical patent/MA27737A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

L'invention concerne des dérivés d'acide acétique substitués cycloalkyle-méthoxy et leurs sels physiologiquement acceptables ainsi que des dérivés physiologiquement fonctionnels. La présente invention porte également sur des composés de formule (I), dans laquelle les groupes ont les significations indiquées, et sur leurs sels physiologiquement acceptables, ainsi que sur des procédés pour les produire. Ces composés sont utiles, par exemple, au traitement et/ou à la prévention de troubles du métabolisme des acides gras, de troubles de la transformation du glucose et de troubles oé la résistance à l'insuline joue un rôle.
MA28460A 2003-02-27 2005-08-26 Dérivés de l'acide 3-(2-phényloxazol-4-ylméthoxy)cyclohexylméthoxyacétique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose MA27737A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
MA27737A1 true MA27737A1 (fr) 2006-02-01

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
MA28459A MA27736A1 (fr) 2003-02-27 2005-08-26 Dérivés de l'acide 3-méthyl-2-(3-(2-phényloxazol-4-ylméthoxy)cyclohexanecarbonylaminobutyrique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose
MA28465A MA27742A1 (fr) 2003-02-27 2005-08-26 Les dérivés et les composés correspondants à l'acide 4-(3-(2-phénelozol-4-ylméthoxy)cyclohexyloxy)butanoique comme modulateurs du PPAR dans le traitement du diabète de Type 2 et de l'athérosclérose.
MA28460A MA27737A1 (fr) 2003-02-27 2005-08-26 Dérivés de l'acide 3-(2-phényloxazol-4-ylméthoxy)cyclohexylméthoxyacétique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA28459A MA27736A1 (fr) 2003-02-27 2005-08-26 Dérivés de l'acide 3-méthyl-2-(3-(2-phényloxazol-4-ylméthoxy)cyclohexanecarbonylaminobutyrique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose
MA28465A MA27742A1 (fr) 2003-02-27 2005-08-26 Les dérivés et les composés correspondants à l'acide 4-(3-(2-phénelozol-4-ylméthoxy)cyclohexyloxy)butanoique comme modulateurs du PPAR dans le traitement du diabète de Type 2 et de l'athérosclérose.

Country Status (34)

Country Link
US (5) US7335671B2 (fr)
EP (3) EP1599453B1 (fr)
JP (3) JP2006519193A (fr)
KR (3) KR20050105492A (fr)
CN (3) CN100398526C (fr)
AR (3) AR043433A1 (fr)
AT (3) ATE365159T1 (fr)
AU (3) AU2004215673B2 (fr)
BR (3) BRPI0407907A (fr)
CA (3) CA2516620A1 (fr)
CL (2) CL2004000392A1 (fr)
CO (2) CO5690580A2 (fr)
DE (4) DE10308355A1 (fr)
DK (3) DK1599453T3 (fr)
EC (2) ECSP055986A (fr)
ES (3) ES2329366T3 (fr)
HR (3) HRP20050742A2 (fr)
IL (2) IL170314A (fr)
MA (3) MA27736A1 (fr)
MX (3) MXPA05008951A (fr)
NO (3) NO20054408L (fr)
OA (2) OA13034A (fr)
PA (1) PA8596801A1 (fr)
PE (3) PE20040959A1 (fr)
PL (3) PL378437A1 (fr)
PT (3) PT1599455E (fr)
RS (1) RS20050594A (fr)
RU (3) RU2005130002A (fr)
SA (1) SA04250153A (fr)
TN (2) TNSN05204A1 (fr)
TW (3) TW200500349A (fr)
UY (2) UY28210A1 (fr)
WO (3) WO2004076428A1 (fr)
ZA (2) ZA200505768B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
RU2008112198A (ru) 2005-09-29 2009-10-10 Санофи-Авентис (Fr) Производные фенил-1,2,4-оксадиазолона, способы их получения и их применение в качестве фармацевтических средств
WO2008018138A1 (fr) 2006-08-10 2008-02-14 Wood One Co., Ltd. Composition hypoglycémique contenant un composant issu de l'écorce d'un arbre appartenant au genre acacia
CN101801906A (zh) 2007-08-16 2010-08-11 索尔维公司 制备4-氟取代的3-氧代-烷酸酯的方法
CN103360290B (zh) * 2008-02-29 2015-04-01 日产化学工业株式会社 噻吩化合物及其中间体的制造方法
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
EP4050422B1 (fr) 2017-12-13 2024-11-20 Canon Kabushiki Kaisha Cartouche et appareil de formation d'images
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CA2241567A1 (fr) 1996-01-17 1997-07-24 Novo Nordisk A/S Derives de 1,2,4-thiadiazine fusionnee et de 1,4-thiazine fusionnee, leur preparation et utilisation
KR100556067B1 (ko) 1996-08-30 2006-03-07 노보 노르디스크 에이/에스 지엘피 - 1 유도체
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
IL127296A (en) 1996-12-31 2003-01-12 Reddy Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
RU2215004C2 (ru) 1997-07-16 2003-10-27 Ново Нордиск А/С Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE69941777D1 (de) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
KR100613175B1 (ko) * 1998-08-27 2006-08-17 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
EP1173438A1 (fr) 1999-04-16 2002-01-23 Novo Nordisk A/S Imidazoles substitues, leur preparation et utilisation
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
CN1331862C (zh) 1999-04-28 2007-08-15 萨诺费－阿文蒂斯德国有限公司 作为ppar受体配体的二芳基酸衍生物
CZ20013834A3 (cs) * 1999-04-28 2002-04-17 Aventis Pharma Deutschland Gmbh Deriváty kyselin se třemi arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují
CA2371271A1 (fr) 1999-04-30 2000-11-09 Neurogen Corporation Derives 9h-pyrimido[4,5-b]indoles: ligands specifiques de crf1
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
DE60029446T2 (de) 1999-06-18 2007-02-08 Merck & Co., Inc. Arylthiazolidindione und aryloxazolidindion-derivate
JP2003504082A (ja) 1999-07-09 2003-02-04 コヘージョン テクノロジーズ， インコーポレイテッド エカリンポリペプチド、エカリンをコードするポリヌクレオチド、及びその利用のための方法
US6967201B1 (en) 1999-07-29 2005-11-22 Eli Lilly And Company Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
CA2383781A1 (fr) * 1999-09-01 2001-03-08 Aventis Pharma Deutschland Gmbh Derives de sulfonylcarboxamide, leur procede de production et leur utilisation comme medicaments
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
MXPA02005327A (es) 1999-12-03 2002-12-06 Astrazeneca Ab Forma cristalina del acido (s)-2- etoxi- 3-(4-(2-(4- metanosulfoniloxifenil) etoxi) fenil) propanoico.
ES2525041T3 (es) 2000-03-31 2014-12-16 Royalty Pharma Collection Trust Método para la mejora de la señalización de islotes en diabetes mellitus y para su prevención
IL152224A0 (en) 2000-04-25 2003-05-29 Kyorin Seiyaku Kk Stable crystals of thiazolidinedione derivative and process for the preparation thereof
WO2001083451A1 (fr) 2000-04-28 2001-11-08 Asahi Kasei Kabushiki Kaisha Nouveaux composés bicycliques
WO2001085695A1 (fr) 2000-05-11 2001-11-15 Bristol-Myers Squibb Co. Analogues de tetrahydroisoquinoline servant de secretagogues d'hormones de croissance
WO2001091752A1 (fr) 2000-05-30 2001-12-06 Merck & Co., Inc. Agonistes du recepteur de la melanocortine
YU91002A (sh) * 2000-06-09 2006-05-25 Aventis Pharma Deutschland Derivati acilfenil-karbamida, postupak za njihovu proizvodnju i njihova primena kao leka
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (fr) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Procédé pour l'identification de composés inhibant la protéolyse de IkB par l'ubiquitine
AU2001284658A1 (en) 2000-08-23 2002-03-13 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
DK1313716T3 (da) * 2000-08-23 2007-08-27 Lilly Co Eli Oxazolyl-arylpropionsyrederivater og anvendelse deraf som PPAR-agonister
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
JPWO2002046146A1 (ja) 2000-12-05 2004-04-08 杏林製薬株式会社 置換カルボン酸誘導体
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
DE50111751D1 (de) 2000-12-21 2007-02-08 Sanofi Aventis Deutschland Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
CZ20031772A3 (cs) * 2000-12-25 2003-11-12 Ono Pharmaceutical Co., Ltd. Derivát dihydronaftalenu a činidlo obsahující tento derivát jako účinnou složku
WO2002064549A1 (fr) * 2001-02-15 2002-08-22 Pfizer Products Inc. Agonistes des ppar
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
CN1578659A (zh) * 2001-06-07 2005-02-09 伊莱利利公司 过氧化物酶体增殖剂激活的受体(ppar)的调节剂
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003004458A1 (fr) 2001-07-03 2003-01-16 Biovitrum Ab Composes nouveaux
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
DE50208960D1 (de) 2001-08-31 2007-01-25 Sanofi Aventis Deutschland Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar-aktivatoren
AU2003207432A1 (en) 2002-02-05 2003-09-02 Eli Lilly And Company Urea linker derivatives for use as ppar modulators
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
AU2003259131A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
AU2004215673A1 (en) 2004-09-10
CL2004000391A1 (es) 2005-01-07
DE502004009690D1 (de) 2009-08-13
PL378437A1 (pl) 2006-04-03
MXPA05008951A (es) 2005-11-04
ES2287700T3 (es) 2007-12-16
BRPI0407907A (pt) 2006-02-14
ECSP055986A (es) 2006-01-16
CA2517386A1 (fr) 2004-09-10
TNSN05204A1 (en) 2007-06-11
CL2004000392A1 (es) 2005-04-22
CN100398526C (zh) 2008-07-02
MXPA05008988A (es) 2005-10-18
AU2004215672A1 (en) 2004-09-10
CN100439345C (zh) 2008-12-03
AU2004215672B2 (en) 2010-01-07
AR043432A1 (es) 2005-07-27
EP1599453B1 (fr) 2009-05-06
ZA200505768B (en) 2005-11-23
TW200500349A (en) 2005-01-01
PT1599455E (pt) 2009-09-29
US20080167354A1 (en) 2008-07-10
EP1599453A1 (fr) 2005-11-30
DK1599455T3 (da) 2009-11-09
TW200508210A (en) 2005-03-01
TNSN05206A1 (en) 2007-06-11
JP2006519199A (ja) 2006-08-24
CO5690578A2 (es) 2006-10-31
DE10308355A1 (de) 2004-12-23
US20080015238A1 (en) 2008-01-17
CO5690580A2 (es) 2006-10-31
US20040209920A1 (en) 2004-10-21
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
ZA200505765B (en) 2006-05-31
DK1599453T3 (da) 2009-08-24
JP2006519194A (ja) 2006-08-24
DK1599452T3 (da) 2007-10-01
WO2004076428A1 (fr) 2004-09-10
RU2005129995A (ru) 2006-01-27
WO2004076426A1 (fr) 2004-09-10
AR043433A1 (es) 2005-07-27
MA27742A1 (fr) 2006-02-01
MXPA05008995A (es) 2005-10-18
UY28209A1 (es) 2004-09-30
AU2004215677A1 (en) 2004-09-10
PL377735A1 (pl) 2006-02-20
EP1599452B1 (fr) 2007-06-20
DE502004009453D1 (de) 2009-06-18
ES2326418T3 (es) 2009-10-09
NO20054398D0 (no) 2005-09-22
PE20040959A1 (es) 2005-01-17
WO2004076427A1 (fr) 2004-09-10
CN1753881A (zh) 2006-03-29
US7365084B2 (en) 2008-04-29
NO20054408D0 (no) 2005-09-22
CN1756748A (zh) 2006-04-05
US20050101637A1 (en) 2005-05-12
TW200510352A (en) 2005-03-16
MA27736A1 (fr) 2006-02-01
KR20050106462A (ko) 2005-11-09
PE20050293A1 (es) 2005-05-24
US7872034B2 (en) 2011-01-18
PT1599452E (pt) 2007-09-12
AU2004215677B2 (en) 2010-01-07
CA2516620A1 (fr) 2004-09-10
ATE365159T1 (de) 2007-07-15
CA2517381A1 (fr) 2004-09-10
OA13035A (en) 2006-11-10
BRPI0407814A (pt) 2006-02-14
ATE430738T1 (de) 2009-05-15
UY28210A1 (es) 2004-09-30
SA04250153A (ar) 2005-12-03
PT1599453E (pt) 2009-07-14
ECSP055985A (es) 2006-01-16
BRPI0407758A (pt) 2006-02-14
ES2329366T3 (es) 2009-11-25
AU2004215673B2 (en) 2009-10-01
NO20054396L (no) 2005-11-11
RS20050594A (sr) 2007-12-31
PE20050292A1 (es) 2005-05-24
EP1599455B1 (fr) 2009-07-01
KR20050106461A (ko) 2005-11-09
ATE435217T1 (de) 2009-07-15
AR043427A1 (es) 2005-07-27
KR20050105492A (ko) 2005-11-04
NO20054396D0 (no) 2005-09-22
EP1599452A1 (fr) 2005-11-30
US20050215596A1 (en) 2005-09-29
IL170314A (en) 2010-11-30
RU2005130002A (ru) 2006-01-27
PL378130A1 (pl) 2006-03-06
CN1753879A (zh) 2006-03-29
RU2005129992A (ru) 2006-02-10
NO20054398L (no) 2005-11-02
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
CN100439347C (zh) 2008-12-03
EP1599455A1 (fr) 2005-11-30
HRP20050742A2 (en) 2006-09-30
JP2006519193A (ja) 2006-08-24
US7335671B2 (en) 2008-02-26
DE502004004139D1 (de) 2007-08-02
US7259177B2 (en) 2007-08-21
OA13034A (en) 2006-11-10
HRP20050744A2 (en) 2006-09-30

Similar Documents

Publication Publication Date Title
MA27737A1 (fr) Dérivés de l'acide 3-(2-phényloxazol-4-ylméthoxy)cyclohexylméthoxyacétique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose
MA27741A1 (fr) Derives diarylcycloalkyles , procede pour leur production, et leur utilisation en tant que medicaments
DE69511687T2 (de) Substituierte azetidinon-verbindungen als hypocholesterolemische mittel
MA31841B1 (fr) Modulateurs du gpr40 à biphényle substitué
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
AU2004229418B2 (en) Compounds for the treatment of metabolic disorders
Watanabe et al. Structure–activity relationship of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone)
MA29804B1 (fr) Derives de phenyl-et pyridyl-1,2,4-oxadiazolone renfermant un groupe phenyle, procedes pour leur preparation et leur utilisation en tant qu'agents pharmaceutiques
ATE264337T1 (de) Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
MA28130A1 (fr) Derives aryle et heteroaryle condenses utilises comme modulateurs du metabolisme et prophylaxie et traitement des troubles metaboliques.
CN101511350A (zh) 二氧代烷与二氧代烯
MA31094B1 (fr) Utilisation de dérivés de pyranone-acide substituée pour le traitement du syndrome métabolique
JP2009528275A (ja) 代謝障害を処置するための化合物
MA29942B1 (fr) Nouveaux derives d'hydroxy-acides gras insatures et leur utilisation dermocosmetologique
AU2004266673B2 (en) Compounds for the treatment of metabolic disorders
MA27738A1 (fr) Dérivés de cycloalkyle 1,3-substitués contenant des groupes acides, principalement hétérocycliques, procédés de préparation correspondants et utilisation desdits dérivés en tant que médicaments
EP0915850A1 (fr) Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation et leurs utilisations en therapeutique
RU2011119533A (ru) Композиции и способы для лечения нарушений деятельности, связанных с ренин-ангиотензин-альдостероновой системой (раас)
Clark et al. 5-(Alkylsulfonyl) salicylanilides as potential dental antiplaque agents
ATE345787T1 (de) Verwendung von cyclohexenon derivaten zur herstellung eines medikaments für die behandlung von dysurie
MA27740A1 (fr) Dérivés arylcycloalkylés comportant des chaines latérales ramifiées servant de modulateurs du récepteur PPAR, procédé pour les préparer, et leur utilisation en tant que médicaments
MA29793B1 (fr) Derives d'imidazole pour le traitement de troubles neurologiques.
MA27195A1 (fr) Derives d'acyl-3 -carboxyphenyluree, procedes pour les preparer et leur utilisation.
US7893304B2 (en) Hydroquinone long-chain derivatives and/or phenoxy long-chain derivatives, and pharmaceuticals comprising the same
CA2219455C (fr) Utilisation de derives de pyrrolidine au traitement de l'alcoolisme